GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference
February 08, 2022 09:00 ET
|
GeoVax, Inc.
Atlanta, GA, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
GeoVax Announces Closing of $10 Million Private Placement
January 20, 2022 09:00 ET
|
GeoVax, Inc.
Atlanta, GA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
GeoVax Announces $10 Million Private Placement
January 14, 2022 08:41 ET
|
GeoVax, Inc.
Atlanta, GA, Jan. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial
January 13, 2022 09:00 ET
|
GeoVax, Inc.
Activities Underway to Expand and Accelerate Enrollment of Ongoing Study for Head and Neck Cancer ATLANTA, GA, Jan. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq:...
GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer
January 11, 2022 09:00 ET
|
GeoVax, Inc.
Atlanta, GA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies,...
GeoVax to Participate in Upcoming Life Sciences Investor Conferences
January 05, 2022 09:00 ET
|
GeoVax, Inc.
Conference Presentation to Include Updates on Three Ongoing Phase 2 Clinical Trials for COVID-19 and Cancer Atlanta, GA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs,...
GeoVax Issues Shareholder Update Letter
January 04, 2022 09:00 ET
|
GeoVax, Inc.
Letter from CEO Describes Achievements during 2021 and Sets Forth New Goals for 2022 ATLANTA, GA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster
December 15, 2021 09:00 ET
|
GeoVax, Inc.
Ongoing Phase 1/2 Trial Advancing to Phase 2 Evaluation of Multi-Antigen Vaccine, Targeting both Spike and Nucleocapsid Proteins, as a Universal Booster to Current FDA-Approved Vaccines ATLANTA, GA,...
GeoVax Receives Notice of Allowance for Malaria Vaccine Patent
December 14, 2021 09:00 ET
|
GeoVax, Inc.
The GeoVax Multi-antigenic MVA-VLP Approach Designed to Provide a Stronger, Broader Protection Atlanta, GA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq:...
GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress
December 03, 2021 09:00 ET
|
GeoVax, Inc.
Nonhuman Primate Testing of Sudan and Marburg Vaccine Candidates Demonstrates Efficacious Immune Response ATLANTA, GA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc....